Immuneering soars on positive trial data for pancreatic cancer therapy

Immuneering

07/01/2025 12:53

** Shares of therapy developer Immuneering  IMRX.O  rise
101.7% to $4.76 premarket
    ** Co says its therapy, IMM-1-104, showed an overall
response rate of 43% in combination with gemcitabine during a
mid-stage trial for patients with pancreatic cancer 
    ** IMRX will expand the trial to include three combination
treatment arms this year in addition to the existing three arms
    ** Co says it expects further trial data in Q2 2025
    ** Up to last close, stock down 64.8% in the previous 12
months  

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))